Pfizer inks deal with rival drug maker Sanofi to pick up production slack

Pfizer retooling has impacted Canadian plans to have everyone vaccinated on schedule

French drugmaker Sanofi has agreed to pick up the slack as Pfizer addresses some production issues.

RELATED: ONTARIO TINKERS WITH COVID-19 VACCINATION PLAN DUE TO PFIZER DELAYS

Sanofi has granted access to a production facility in Frankfurt and will start producing doses of the Pfizer BioNTech COVID-19 vaccine. In a statement released by Sanofi on Wednesday, it said the deal with Pfizer means it will produce more than 125 million doses for the European Union, with first deliveries expected in the summer.

This marks the first time a drugmaker will produce a rival’s vaccine according to representatives at Sanofi. It comes as Pfizer’s Belgium production facility goes through retooling to increase production. The subsequent decline in its COVID-19 vaccine has led to a restructuring of Canada’s and Ontario’s plan to vaccinate everyone who wants to be by this fall1.

RELATED: CANADA TO RECEIVE NO PFIZER COVID-19 VACCINE DELIVERIES IN THE LAST WEEK OF JANUARY

Sanofi is among the pharmaceutical companies that continue to press ahead with the development of a COVID-19 vaccine of its own.

Tweet
Share
Share
Pin